Analysts expect that Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) will post $2.62 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Synergy Pharmaceuticals’ earnings. The lowest sales estimate is $2.60 million and the highest is $2.63 million. The business is expected to announce its next earnings report on Monday, August 14th.

According to Zacks, analysts expect that Synergy Pharmaceuticals will report full-year sales of $2.62 million for the current financial year, with estimates ranging from $18.00 million to $34.09 million. For the next financial year, analysts expect that the company will post sales of $143.04 million per share, with estimates ranging from $84.00 million to $202.08 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Synergy Pharmaceuticals.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.07. The business had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.10 million.

SGYP has been the topic of a number of analyst reports. Citigroup Inc. cut shares of Synergy Pharmaceuticals from a “neutral” rating to a “sell” rating in a report on Thursday, April 6th. Cantor Fitzgerald initiated coverage on shares of Synergy Pharmaceuticals in a report on Thursday, June 1st. They issued an “overweight” rating and a $11.00 price target on the stock. ValuEngine cut shares of Synergy Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 23rd. Zacks Investment Research raised shares of Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Oppenheimer Holdings, Inc. set a $9.00 price target on shares of Synergy Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 10th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $10.67.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/22/synergy-pharmaceuticals-inc-sgyp-expected-to-announce-quarterly-sales-of-2-62-million.html.

Institutional investors have recently made changes to their positions in the stock. Tudor Investment Corp Et Al increased its stake in shares of Synergy Pharmaceuticals by 1.3% in the fourth quarter. Tudor Investment Corp Et Al now owns 18,376 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 232 shares during the period. Amalgamated Bank increased its stake in shares of Synergy Pharmaceuticals by 7.9% in the first quarter. Amalgamated Bank now owns 24,013 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,758 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Synergy Pharmaceuticals by 27.4% in the first quarter. Janney Montgomery Scott LLC now owns 30,200 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 6,500 shares during the period. Stifel Financial Corp increased its stake in shares of Synergy Pharmaceuticals by 34.4% in the first quarter. Stifel Financial Corp now owns 30,289 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 7,750 shares during the period. Finally, Principal Financial Group Inc. increased its stake in shares of Synergy Pharmaceuticals by 12.9% in the first quarter. Principal Financial Group Inc. now owns 37,343 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 4,267 shares during the period. 67.37% of the stock is owned by institutional investors and hedge funds.

Synergy Pharmaceuticals (NASDAQ SGYP) opened at 4.26 on Friday. The company’s market cap is $958.28 million. Synergy Pharmaceuticals has a 1-year low of $3.34 and a 1-year high of $7.15. The firm’s 50-day moving average price is $4.29 and its 200-day moving average price is $4.90.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Get a free copy of the Zacks research report on Synergy Pharmaceuticals (SGYP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.